Tarriff Scott 4
4 · EAGLE PHARMACEUTICALS, INC. · Filed May 15, 2023
Insider Transaction Report
Form 4
Tarriff Scott
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2023-05-11$20.71/sh−15,000$310,650→ 1,624,934 total - Sale
Common Stock
2023-05-12$19.69/sh−3,131$61,649→ 1,621,803 total - Sale
Common Stock
2023-05-12$20.42/sh−11,869$242,365→ 1,609,934 total - Sale
Common Stock
2023-05-15$21.06/sh−14,800$311,688→ 1,595,134 total - Sale
Common Stock
2023-05-15$21.52/sh−200$4,304→ 1,594,934 total
Footnotes (5)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.33 to $20.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4) and (5).
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.15 to $20.11 inclusive.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.15 to $20.745 inclusive.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.4867 to $21.43 inclusive.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.51 to $21.525 inclusive.